This data is in line with a published analysis of 124 patients where patients with BRD-NUT3 or NSD3-NUT-positive fusion tumours were shown to have a better prognosis than patients with nonthoracic or thoracic primary tumours with BRD4-NUT [9]. This evidence concerns the gene NUTM1 and neoplasm.